Cognivia is cracking the code on the complex relationship between patient traits and behavior. We help clinical trials address placebo response, improve patient adherence, and reduce drop out by combining a sophisticated evaluation of patient characteristics and traits with machine learning. See how our solutions are breaking down the barriers to more effective clinical research and patient management.
Cognivia is an innovator of analytical tools to optimize and accelerate the clinical development of new medicines. The privately held company was founded in 2013 by longtime colleagues with decades of experience in the pharmaceutical industry who set out to tackle some of the most challenging issues that prevent drugs from reaching the marketplace. Cognivia helps lessen risk and helps increase clinical trial success.
It can help reduce the variability of study data by 30 percent. This can lead to fewer patients needed in a study, equating to less cost and time. The company offers Placebell©™, a solution that improved clinical trial assay sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies.
Total Funding: $16.5M
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2013
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Cognivia
Dominique Demolle Ph.D
Co-Founder, Chief Executive Officer & Board Member
Chantal Gossuin
Chief Operating Officer